Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

Direct oral anticoagulant therapies, including direct anti-Xa and thrombin inhibitors have
recently been introduced and may have advantages over vitamin K antagonists such as …

Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared
to vitamin K antagonists (VKAs) for the prevention and treatment of venous …

A new generation of antithrombotic agents has recently emerged. These provide direct
inhibition of either thrombin (factor IIa [FIIa]) or FXa, and are increasingly replacing the …

Direct oral anticoagulants (DOAC s), including the direct thrombin inhibitor, dabigatran, and
the direct factor Xa (FX a) inhibitors, rivaroxaban, apixaban and edoxaban, are approved for …

Coagulation tests range from global or overall tests to assays specific to individual clotting
factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant …

Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran)
and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical …

The use of oral anticoagulants is becoming increasingly common. For many years warfarin
was the main oral anticoagulant available, but therapeutic options have expanded with the …

Introduction Drug accumulation of rivaroxaban is a concern in patients with chronic kidney
disease (CKD). Data regarding the plasma rivaroxaban levels in early CKD patients and its …

Rivaroxaban and apixaban are selective direct inhibitors of free and prothrombinase-bound
factor Xa (FXa). Surprisingly prothrombin time (PT) is little sensitive to clinically relevant …